ALPA vs PPLPHARMA: Stock Comparison

Alpa Laboratories Limited vs Piramal Pharma Limited

Live data: 22 July 2026, 2:55 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Alpa Laboratories Limited shows a higher ROE, lower leverage and a higher ROCE, while Piramal Pharma Limited shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alpa Laboratories Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ALPA is more favourable on 7 of 13 scored metrics and PPLPHARMA on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹23,554 Cr vs ₹142 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 12.09x
P/B Ratio
ALPA has a lower P/B
0.77x vs 3.01x
EPS
ALPA has higher earnings per share
₹7.14 vs ₹-2.45
Dividend Yield
PPLPHARMA has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
PPLPHARMA has faster revenue growth
-0.1% vs -21.4%
Qtr Sales Growth
PPLPHARMA has stronger quarterly sales growth
-0.08% vs -21.3%
Qtr Profit Growth
ALPA has stronger quarterly profit growth
165% vs -25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALPAPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALPAPPLPHARMA
Live Price₹66.98₹177.46
Day Change-0.98%-3.98%
Volume6,95877.37 L
52-Week High₹105.51₹212.39
52-Week Low₹46.1₹132.3
Distance from 52W High-36.52%-16.45%

Valuation

MetricALPAPPLPHARMA
Market Cap₹142 Cr₹23,554 Cr
P/E Ratio12.09x-75.43x
P/B Ratio0.77x3.01x
EPS₹7.14₹-2.45
Book Value₹32.34₹64.78
Dividend Yield0%0.08%

Growth

MetricALPAPPLPHARMA
Revenue Growth (TTM YoY)-21.4%-0.1%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-21.3%-0.08%
Qtr Profit Growth165%-25%

Profitability & Leverage

MetricALPAPPLPHARMA
ROE8.39%-3.83%
ROCE9.42%2.52%
Net Margin14.33%-3.68%
Operating Margin3.11%10.4%
Debt to Equity0.01x0.7x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALPAPPLPHARMA
Promoter Holding57.19%34.86%
FII Holding0.35% 0.03 pp30.18% 0.52 pp
DII Holding0.07% 0.07 pp15.61% 0.08 pp
Public Holding42.39% 0.04 pp19.01% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alpa Laboratories Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.